Profile: Phenomix Corporation is a biopharmaceutical company focused on the discovery, and development of small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. We offer DPP-4 inhibitors that have a favorable tolerable profile and represent the most recently approved class of agents for the treatment of type 2 diabetes, which prevent the DPP-4 enzyme from breaking down GLP-1, thereby increasing the levels of this hormone in the digestive tract & the blood.